跳至主要内容
临床试验/NCT01368913
NCT01368913已完成不适用

MINRIN® Orally Disintegrating Tablet (Fast Dissolving Desmopressin) and Tablets in Treatment of Primary Nocturnal Enuresis With Special Focus on Patient Satisfaction

Ferring Pharmaceuticals13 个研究点 分布在 1 个国家目标入组 138 人开始时间: 2011年6月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
138
试验地点
13
主要终点
Assessment of patient and parent satisfaction

研究概览

简要总结

Desmopressin in treatment of nocturnal enuresis (bedwetting).

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
5 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Treatment of primary nocturnal enuresis within an overall therapeutical concept, eg, in cases of failure of other non-medicinal therapies or with indication of a medicinal therapy caused by nocturnal ADH deficiency
  • The patients and their parents have been informed about the study and have given their written consent for participation.

排除标准

  • The prescription of Minirin® tablets / Minirin® orally disintegrating tablet (fast dissolving desmopressin) is contraindicated

结局指标

主要结局

Assessment of patient and parent satisfaction

时间窗: 3 months

次要结局

  • Assessment of urine volume(3 months)
  • Assessment of patient compliance(3 months)
  • Number of wet nights(3 months)
  • Assessment of drinking volume(3 months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (13)

Loading locations...

相似试验